Bendamustine: A new look at an old drug

Cancer

Volumn 115, Issue 3, 2009, Pages 473-479

  Kalaycio, Matt ^a,b  

^a Cleveland Clinic ^*  (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Alkylating agents; Bendamustine; Chronic lymphocytic leukemia; Indolent b cell non hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA;

EID: 60049088480     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24057     Document Type: Review

References (31)

1. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin- resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415-421.
2. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta. 1972;287:386-389.
3. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-317.
4. Leoni LM, Bailey B, Niemeyer CC, et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. AACR Meeting Abstracts. 2004;2004:278-b.
5. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol. 2002;128:271-278.
6. Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485-493.
7. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase- I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pretreated patients with B-chronic lymphocytic leukaemia (binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006;132:99-104.
8. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. Semin Oncol. 2002;29:27-32.
9. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 2001;12:725-729.
10. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007;(4):CD003805.
11. Maloney DG. Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep. 2005;4:39-45.
12. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multi- center, single-agent study. J Clin Oncol. 2008;26:204-210.
13. Kanekal S, Crain B, Elliott G, Singh SS. SDX-105 (bendamustine) inhibits growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID mice. AACR Meeting Abstracts. 2004;2004:1057.
14. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12-14.
15. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
16. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
17. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL study group. Haematologica. 2005;90:1357-1364.
18. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. ASH Annual Meeting Abstracts. 2007;110:2043.
19. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
20. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370:230-239.
21. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891.
22. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludara-bine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol. 2007;25:793-798.
23. Kalaycio M. Unconjugated monoclonal antibodies. In: Kalaycio M, ed. Biologic Therapy of Leukemia. Totowa, NJ: Humana Press; 2003:29.
24. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
25. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
26. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG). ASH Annual Meeting Abstracts. 2007;110: 3106.
27. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma. 2004;45:911-913.
28. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/mitoxantrone/ rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma. 2004;45:2445-2449.
29. Ponisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol. 2002;29:23-26.
30. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. JClin Oncol. 2005;23:3383-3389.
31. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623.